Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
Jazyk angličtina Země Nový Zéland Médium print
Typ dokumentu časopisecké články
PubMed
27541802
DOI
10.1007/s40266-016-0390-1
PII: 10.1007/s40266-016-0390-1
Knihovny.cz E-zdroje
- MeSH
- čas zasáhnout při rozvinutí nemoci MeSH
- indoly aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- karcinom z renálních buněk farmakoterapie patologie MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádory ledvin farmakoterapie patologie MeSH
- přežití bez známek nemoci MeSH
- progrese nemoci MeSH
- protinádorové látky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- pyrroly aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- registrace MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sunitinib MeSH
- věkové faktory MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- indoly MeSH
- protinádorové látky MeSH
- pyrroly MeSH
- sunitinib MeSH
BACKGROUND: Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. PATIENTS AND METHODS: The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged <70 and ≥70 years, respectively. RESULTS: Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged <70 and ≥70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. CONCLUSIONS: The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Czech Republic
Department of Oncology and Radiotherapy University Hospital Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Zobrazit více v PubMed
Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72 PubMed
Expert Rev Anticancer Ther. 2016;16(3):323-34 PubMed
Med Oncol. 2012 Dec;29(5):3314-20 PubMed
Br J Cancer. 2014 Mar 4;110(5):1125-32 PubMed
Ann Oncol. 2013 Feb;24(2):336-42 PubMed
Eur J Cancer. 2009 Jan;45(2):228-47 PubMed
J Clin Oncol. 2002 Jan 1;20(1):289-96 PubMed
Lancet Oncol. 2009 Aug;10 (8):757-63 PubMed
Cancer Treat Rev. 2008 May;34(3):193-205 PubMed
J Clin Oncol. 2009 Aug 1;27(22):3584-90 PubMed
